Market revenue in 2021 | USD 15.6 million |
Market revenue in 2030 | USD 93.1 million |
Growth rate | 22% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.69% in 2021. Horizon Databook has segmented the Brazil non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
To bridge knowledge & skill gaps and adopt strategies to improve patient care, such as implementing pertinent care pathways, promoting testing & referrals, and multidisciplinary teamwork, educational interventions are required.
In addition to the high regional rates of obesity and type 2 diabetes mellitus, inadequate disease awareness, stark social disparities, and fragmented healthcare systems, with poor communication between experts & between different levels of care, pose challenges to the proper diagnosis and management of NAFLD.
Moreover, there is little knowledge of the illness among national decision-makers, and there are no solid measures in place to deal with a fast-expanding health issue. Healthcare workers' lack of awareness causes under diagnosis, low referral rates, and delayed intervention in patients at risk of liver and metabolic problems.
Horizon Databook provides a detailed overview of country-level data and insights on the Brazil non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Brazil non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account